DE69334133D1 - Chemisch definierten nicht-polymer wertigen Plattformmolokülen und ihren Konjugaten - Google Patents

Chemisch definierten nicht-polymer wertigen Plattformmolokülen und ihren Konjugaten

Info

Publication number
DE69334133D1
DE69334133D1 DE69334133T DE69334133T DE69334133D1 DE 69334133 D1 DE69334133 D1 DE 69334133D1 DE 69334133 T DE69334133 T DE 69334133T DE 69334133 T DE69334133 T DE 69334133T DE 69334133 D1 DE69334133 D1 DE 69334133D1
Authority
DE
Germany
Prior art keywords
conjugates
polymer
platform molecules
chemically defined
defined non
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69334133T
Other languages
English (en)
Other versions
DE69334133T2 (de
Inventor
Stephen Coutts
David S Jones
Douglas Alan Livingston
Lin Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
La Jolla Pharmaceutical Co
Original Assignee
La Jolla Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/118,055 external-priority patent/US6060056A/en
Priority claimed from US08/152,506 external-priority patent/US5552391A/en
Application filed by La Jolla Pharmaceutical Co filed Critical La Jolla Pharmaceutical Co
Application granted granted Critical
Publication of DE69334133D1 publication Critical patent/DE69334133D1/de
Publication of DE69334133T2 publication Critical patent/DE69334133T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
DE69334133T 1993-09-08 1993-12-03 Chemisch definierten nicht-polymer wertigen Plattformmolokülen und ihren Konjugaten Expired - Fee Related DE69334133T2 (de)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US118055 1993-09-08
US08/118,055 US6060056A (en) 1991-02-08 1993-09-08 Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule
US14259893A 1993-10-22 1993-10-22
US142598 1993-10-22
US152506 1993-11-15
US08/152,506 US5552391A (en) 1990-01-16 1993-11-15 Chemically-defined non-polymeric valency platform molecules and conjugates thereof
EP93309288 1993-11-22
EP93309288 1993-11-22

Publications (2)

Publication Number Publication Date
DE69334133D1 true DE69334133D1 (de) 2007-05-31
DE69334133T2 DE69334133T2 (de) 2007-12-27

Family

ID=38015477

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69334133T Expired - Fee Related DE69334133T2 (de) 1993-09-08 1993-12-03 Chemisch definierten nicht-polymer wertigen Plattformmolokülen und ihren Konjugaten

Country Status (6)

Country Link
EP (2) EP1808183A3 (de)
AT (1) ATE359830T1 (de)
DE (1) DE69334133T2 (de)
DK (1) DK0642798T3 (de)
ES (1) ES2282988T3 (de)
HK (1) HK1014240A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552391A (en) * 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
EP1808183A3 (de) * 1993-09-08 2009-07-01 La Jolla Pharmaceutical Company Chemisch definierte nichtpolymere Valenzplattformmoleküle und Konjugate davon
US6410775B1 (en) 1995-06-07 2002-06-25 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
US5874409A (en) * 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
CN1166172A (zh) * 1995-08-03 1997-11-26 达德化学系统公司 奎尼定缀合物及其在免疫测定中的应用
EP0954531A1 (de) * 1996-06-06 1999-11-10 Lajolla Pharmaceutical Company Apl-immunreaktive peptide, deren konjugate und verfahren zur behandlung von apl-antikörpern vermittelten krankheiten
EP0855403A1 (de) * 1996-06-10 1998-07-29 Laboratory of Molecular Biophotonics Photosplatbare zyklische oligonukleotide
US7094943B2 (en) * 1998-04-27 2006-08-22 Hubert Köster Solution phase biopolymer synthesis
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
US6458953B1 (en) 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
US6399578B1 (en) * 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
AU779887B2 (en) * 1999-06-08 2005-02-17 La Jolla Pharmaceutical Company Valency platform molecules comprising aminooxy groups
CA2391944A1 (en) 1999-11-28 2001-06-14 Lajolla Pharmaceutical Company Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof
WO2001093914A2 (en) * 2000-06-08 2001-12-13 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
CA2799202C (en) * 2010-05-18 2016-07-05 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2524586B2 (ja) * 1985-06-26 1996-08-14 シタス コーポレイション ポリマ−接合を利用する医薬組成物用蛋白質の可溶化
US4904582A (en) * 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5162515A (en) * 1990-01-16 1992-11-10 La Jolla Pharmaceutical Company Conjugates of biologically stable polymers and polynucleotides for treating systemic lupus erythematosus
US5552391A (en) * 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
EP1808183A3 (de) * 1993-09-08 2009-07-01 La Jolla Pharmaceutical Company Chemisch definierte nichtpolymere Valenzplattformmoleküle und Konjugate davon

Also Published As

Publication number Publication date
ES2282988T3 (es) 2007-10-16
DK0642798T3 (da) 2007-09-10
EP1808183A2 (de) 2007-07-18
ATE359830T1 (de) 2007-05-15
DE69334133T2 (de) 2007-12-27
HK1014240A1 (en) 1999-09-24
EP0642798A2 (de) 1995-03-15
EP0642798A3 (de) 1998-09-16
EP1808183A3 (de) 2009-07-01
EP0642798B1 (de) 2007-04-18

Similar Documents

Publication Publication Date Title
CA2171434A1 (en) Chemically-defined non-polymeric valency platform molecules and conjugates thereof
DE69334133D1 (de) Chemisch definierten nicht-polymer wertigen Plattformmolokülen und ihren Konjugaten
DE69834693D1 (de) Zusammensetzung zur behandlung von elastischen polyurethanfasern und die damit behandelten fasern
DE68906984D1 (de) Apparat zur durchfuehrung von sich wiederholenden chemischen reaktionen.
DE69533634D1 (de) Geranylgeranyldiphosphate-Synthase und diese kodierende DNA
DE69637156D1 (de) Dna-molekül, herstellung und verwendung in der gentherapie
DE69920334D1 (de) Übergangsmetallverbindungen und diese enthaltende Katalysatoren zur Polymerisierung von Olefinen
DE69401661D1 (de) Nukleinsaeure-analog testverfahren
DE69421193D1 (de) Mittel und Verfahren zur Metallbehandlung
DE69407870T2 (de) Fluorierungskatalysator und Fluorierungsverfahren
ATE342911T1 (de) Synthese von nukleosiden und polynukleotiden
DE69526935T2 (de) Verwendung von mycobacterium zur tumorbehandlung
DE69422716D1 (de) Methode zur verbesserung der oxydation und ammoxydationskatalysatoren
DE69019886D1 (de) Katheter und Instrumentarium zur extrakorporalen Zirkulation.
NO900696D0 (no) Fremgangsmaate og anordning for biologisk behandling omfattende nitrifisering og denitrifisering av avloepsvann.
DE69431825D1 (de) Delta-9 Desaturase und dafür kodierendes Gen
DE69331630T2 (de) Verfahren zur inaktivierung von nukleotidsequenzen und dafür verwendbare metallchelate
EP0749312A4 (de) DIROFILARIA IMMITIS - Gp29 - PROTEINE, NUKLEINSÄUREMOLEKÜLE UND IHRE VERWENDUNGEN
DE69714504T2 (de) Benzothiopene, diese enthaltende Zubereitungen und Verfahren
ATE202130T1 (de) Behandelte kohlenstoffartige zusammensetzungen und verbesserte polymerzusammensetzungen
DE69431544T2 (de) Biochemischer Analysator und Inkubator dafür
DE69205344D1 (de) Wasserstoffbehandlungskatalysator und Verfahren.
ATE276752T1 (de) Verwendung von niedermolekularen heparinen zur vorbeugung und behandlung von einem trauma des zentralnervensystems
DE69816776D1 (de) Modifizierte Katalase, diese enthaltende Zusammensetzung und Verfahren zur Herstellung der Katalase
DE69410971D1 (de) Verfahren zur Inaktivierung von Katalaseenzym

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee